Notable Analyst Rating Changes 01/15: (VPHM) (BSX) (GMCR) Upgraded; (HL) (ARMH) (AMTD) Downgraded

January 15, 2013 11:00 AM EST Send to a Friend
UPGRADES
BofA/Merrill Lynch upgrades ViroPharma (Nasdaq: VPHM) from Neutral to Buy.

Credit Suisse raises Boston Scientific (NYSE: BSX) from Neutral to Outperform.

Deutsche Bank boosts Cliffs Natural Resources (NYSE: CLF) from Hold to Buy, moving its price target from $40 to $48.

Argus lifts Green Mountain Coffee Roasters (NASDAQ: GMCR) from Hold to Buy.

For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades

DOWNGRADES
Deutsche Bank trims Hecla Mining (NYSE: HL) from Hold to Sell. Click Here for more color.

Morgan Stanley downgrades ARM Holdings (Nasdaq: ARMH) from Overweight to Equalweight and price target of £9.11.

Sterne Agee lowers TD Ameritrade (NYSE: AMTD) from Buy to Neutral with a price target of $19.

JPMorgan cuts US Airways Group (NYSE: LCC) from Overweight to Neutral with a price target of $18.

For daily real-time Downgrades go to http://www.streetinsider.com/downgrades

NEW COVERAGE
Baird initiates Duke Realty (NYSE: DRE) with a Outperform and price target of $16.

Lazard Capital starts Nektar Therapeutics (Nasdaq: NKTR) at Buy and $15 target.

UBS begins Vantiv (NYSE: VNTV) with a Neutral and price target of $22.

Sterne Agee assumes E*TRADE (Nasdaq: ETFC) at Buy and $11 target.

For daily real-time New Coverage go to http://www.streetinsider.com/New+Coverage

Visit our new Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Special Reports

Related Entities

Credit Suisse, Deutsche Bank, UBS, JPMorgan, Morgan Stanley, Merrill Lynch, Robert W Baird, Bank of America, Lazard, Sterne Agee, Argus, Notable Analyst Rating Changes

Add Your Comment